IACH 2021 | Advances in chronic GvHD management

Name: Advances in chronic GvHD management
Uploaded: 2021-09-28T00:00:00Z
Duration: 2 min 34 s

Zinaida Perić • 28 Sep 2021

IACH 2021

Anti-thymocyte globulin Cyclophosphamide Cyclosporine Mycophenolate mofetil

Zinaida Perić, MD, PhD, University Hospital Centre Zagreb, Zagreb, Croatia, gives an overview of her talk on advances in the management of chronic graft-versus-host disease (GvHD). Recent improvements in the treatment of chronic GvHD include antithymocyte globulin (ATG) and post-transplant cyclophosphamide. Clinical trials are currently evaluating the use of post-transplant cyclophosphamide in combination with cyclosporine compared to standard immunosuppression with cyclosporine and mycophenolate mofetil (MMF) and have shown that adding post-transplant cyclophosphamide significantly reduces chronic GvHD and leads to improvements in GvHD-free relapse-free survival. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.